CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for CEL-SCI Corporation for the three-month period ended December 31, 2006. The company is a biopharmaceutical entity focused on the development of Multikine (for cancer treatment) and L.E.A.P.S. technology. The company has not generated revenue from product sales and relies on financing and grants to fund research and development (R&D).
Key Financial Metrics
| Metric | Q1 2007 (Ended Dec 31, 2006) | Q1 2006 (Ended Dec 31, 2005) |
|---|---|---|
| Total Revenue | $20,793 | $29,847 |
| Net Loss | $(1,112,359) | $(997,127) |
| Net Loss Per Share (Diluted) | $(0.01) | $(0.01) |
| Cash and Cash Equivalents | $7,176,818 | $1,885,627 |
| Net Cash Used in Operating Activities | $(935,792) | $(760,186) |
| Total Liabilities | $10,242,133 | N/A |
| Stockholders' Equity (Deficit) | $(1,807,909) | N/A |
Note: The company reported a significant non-cash gain on derivative instruments of $719,247, which reduced the reported net loss. Without this gain, the operating loss would have been significantly higher.
Material Changes vs. Prior Period
- Revenue: Decreased by approximately $9,000 (33%) primarily due to the winding down of grant-funded work.
- Expenses: Total expenses increased by $549,000 (52%).
- R&D Expenses: Increased by $71,269 due to new CEL-1000 projects and preparation for Phase III trials.
- General & Administrative (G&A): Increased by $479,668. Drivers included $110,300 in stock issued to stockholders, $305,000 in public relations costs (stock-based), and $43,900 in accounting fees for derivative valuation.
- Financing: In August 2006, the company issued $8.3 million in Series K Convertible Notes, resulting in net proceeds of $7.73 million. This significantly improved cash balances compared to the prior year.
- Derivatives: A gain of $719,247 was recorded due to changes in the fair value of Series K Notes and Warrants, compared to a gain of only $13,337 in the prior year.
Outlook, Risks, and Management Commentary
- Clinical Progress: In January 2007 (subsequent event), the FDA issued a "no objection" letter allowing the company to proceed with a global Phase III clinical trial for Multikine in head and neck cancer patients.
- Manufacturing: The company signed a letter of intent in January 2007 to acquire a turn-key cGMP manufacturing facility for an estimated $12-14 million via a long-term lease.
- Liquidity: Management believes funds from the Series K Notes and potential external financing are sufficient to meet liabilities through fiscal years 2007 and 2008. However, the company must raise additional capital to continue R&D and commercialization.
- Risks:
- Derivative Volatility: Significant portions of the balance sheet and income statement are driven by the fair value of derivative instruments (warrants and convertible notes), which are subject to market volatility.
- Regulatory Uncertainty: The company cannot predict the timing or success of future clinical trials or regulatory approvals.
- Contingency: The company disputes a $350,000 invoice from its former auditor, Deloitte & Touche, related to a prior restatement and has not recorded it as a liability.
Investor Verification Checklist
- Derivative Valuation: Verify the assumptions used to value the Series K Warrants and Notes, as a $719k gain significantly masked the operating loss.
- Cash Burn Rate: Confirm the sustainability of the $7.1M cash balance given the $935k quarterly operating cash burn and upcoming manufacturing lease commitments.
- Debt Covenants: Review the terms of the Series K Notes, specifically the share-settlement option and the 19.999% issuance cap.
- Auditor Dispute: Monitor the status of the disputed $350k invoice from Deloitte & Touche.
- Phase III Trial Costs: Assess the capital requirements for the newly approved Phase III trial and the $12-14M manufacturing facility.